文献速递睡眠障碍老年精神焦虑、强迫与应激相关障碍

患者自我引导干预减少镇静剂使用并改善睡眠:YAWNS NB随机临床试验

Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

YAWNS NB研究纳入565名65岁及以上长期使用苯二氮䓬受体激动剂(BZRA)的独立生活成人,随机分为YAWNS-1、YAWNS-2或常规治疗(TAU)三组。6个月时,YAWNS-1组的BZRA停药及剂量减少≥25%的比例为46.6%,高于YAWNS-2组的34.8%(P=0.02)和TAU组的20.3%(P<0.001);YAWNS-1在CBTI技术采纳和睡眠结局上也优于YAWNS-2,并较TAU降低失眠严重程度和日间嗜睡。

要点

  • YAWNS-1组停药加剂量减少≥25%合计46.6%,高于YAWNS-2组34.8%和TAU组20.3%。
  • YAWNS-1组新CBTI技术采纳3.1项,优于YAWNS-2组2.4项(P=0.03)。
  • YAWNS-1组睡眠效率变化4.1%,优于YAWNS-2组-1.7%(P=0.001)。

核心结论

  • YAWNS-1作为一种简单、可扩展的直接面向患者的干预,大幅减少了BZRA使用并改善了睡眠结局。
  • 作者认为该干预可在人群层面实施,以转变老年人的失眠照护。

研究设计与样本

  • YAWNS NB研究为三臂、实用性、开放标签、最少接触的随机临床试验,研究始于2020年11月,结束于2022年6月。
  • 参与者来自加拿大新不伦瑞克省各社区,为65岁及以上独立生活、长期使用BZRA且有当前或既往失眠的成人。
  • 参与者被随机分配到YAWNS-1、YAWNS-2或常规治疗(TAU)组;1295人表示感兴趣,565人(43.6%)完成基线评估。
  • 参与者平均(SD)年龄72.1(5.7)岁,平均(SD)BZRA使用时长11.4(9.1)年,女性362人(64.1%)。

主要发现

  • 停药和剂量减少≥25%的比例:YAWNS-1组50/191(26.2%)和39/191(20.4%),合计46.6%;YAWNS-2组38/187(20.3%)和27/187(14.4%),合计34.8%(P=0.02);TAU组14/187(7.5%)和24/187(12.8%),合计20.3%(P<0.001)。
  • 新CBTI技术采纳数量:YAWNS-1组3.1项 vs YAWNS-2组2.4项(P=0.03)。
  • 睡眠效率变化:YAWNS-1组4.1% vs YAWNS-2组-1.7%(P=0.001)。
  • 失眠严重指数变化:YAWNS-1组-2.0 vs TAU组0.3(P<0.001)。
  • Epworth嗜睡量表变化:YAWNS-1组-0.8 vs TAU组0.3(P=0.001)。

关键数值与推荐

  • YAWNS-1组新CBTI技术采纳3.1项,YAWNS-2组2.4项(P=0.03)。
  • YAWNS-1组睡眠效率变化4.1%,YAWNS-2组-1.7%(P=0.001)。
  • YAWNS-1组失眠严重指数变化-2.0,TAU组0.3(P<0.001)。
  • YAWNS-1组Epworth嗜睡量表变化-0.8,TAU组0.3(P=0.001)。

临床怎么用

  • 原文未报告临床实践推荐意见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Direct-to-patient interventions enabling transitions from long-term benzodiazepine receptor agonist (BZRA) use to cognitive behavioral therapy for insomnia (CBTI) by older adults has the potential to reduce BZRA use and related harms while improving sleep outcomes without requiring prearranged clinician involvement. OBJECTIVE: To compare 2 direct-to-patient behavior change interventions with treatment as usual (TAU) on BZRA use, sleep, and other health outcomes, and uptake of CBTI techniques. DESIGN, SETTING, AND PARTICIPANTS: The Your Answers When Needing Sleep in New Brunswick (YAWNS NB) study was a 3-arm, pragmatic, open-label, minimum-contact, randomized clinical trial. The study began November 2020 and ended June 2022. Participants were randomly allocated to 1 of 3 groups, including 2 different mailed behavior change interventions or no intervention (TAU). Participants were from communities across the province of New Brunswick, Canada, and included adults 65 years and older living independently with long-term use of BZRAs and current or past insomnia. INTERVENTIONS: The Sleepwell package (YAWNS-1) consisted of a cover letter and 2 booklets ("How to Stop Sleeping Pills" and "How to Get Your Sleep Back"). The other package (YAWNS-2) included updated versions of the 2 booklets ("You May Be at Risk" and "How to Get a Good Night's Sleep Without Medication") used in the Eliminating Medications Through Patient Ownership of End Results (EMPOWER) study. MAIN OUTCOMES AND MEASURES: BZRA use at 6 months was the primary measure. Secondary measures included CBTI use, sleep, insomnia, daytime sleepiness, safety, anxiety, frailty, and quality of life. RESULTS: A total of 1295 individuals expressed interest in the study, and 565 (43.6%) completed a baseline assessment. Participants had a mean (SD) age of 72.1 (5.7) years, a mean (SD) BZRA use duration of 11.4 (9.1) years, and 362 (64.1%) were female. Discontinuations and dose reductions of 25% or greater were highest with YAWNS-1 (50 of 191 [26.2%]; 39 of 191 [20.4%]; total, 46.6%) compared with YAWNS-2 (38 of 187 [20.3%]; 27 of 187 [14.4%]; total, 34.8%, P = .02) and TAU (14 of 187 [7.5%]; 24 of 187 [12.8%]; total, 20.3%, P < .001). YAWNS-1 also demonstrated better uptake of CBTI techniques and sleep outcomes compared with YAWNS-2 (new CBTI techniques: 3.1 vs 2.4; P =.03; sleep efficiency change: 4.1% vs -1.7%; P =.001) and reduced insomnia severity and daytime sleepiness compared with TAU (insomnia severity index change: -2.0 vs 0.3; P <.001; Epworth Sleepiness Scale change: -0.8 vs 0.3; P =.001). CONCLUSIONS AND RELEVANCE: Results of the YAWNS NB randomized clinical trial show that, as a simple, scalable, direct-to-patient intervention, YAWNS-1 substantially reduced BZRA use and improved sleep outcomes. It could be implemented to transform insomnia care for older adults at the population level. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04406103.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gardner DM, Turner JP, Magalhaes S, et al. Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial. JAMA Psychiatry. 2024. PMID: 39292452. doi:10.1001/jamapsychiatry.2024.2731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。